Inactive Instrument

Calyxt, Inc. Stock Nasdaq

Equities

CBUS

US17166A1016

Advanced Medical Equipment & Technology

Sales 2024 * 2.17M Sales 2025 * 8.69M Capitalization 319M
Net income 2024 * -82M Net income 2025 * -88M EV / Sales 2024 * 147 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 36.7 x
P/E ratio 2024 *
-4.86 x
P/E ratio 2025 *
-6.31 x
Employees 183
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.22%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 71 -
Director of Finance/CFO 67 -
President 61 -
Members of the board TitleAgeSince
Chief Executive Officer 71 -
Director/Board Member 81 -
Director/Board Member 76 -
More insiders
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
More about the company